StreetAlpha.app
Home › Stocks › EXEL

Exelixis, Inc. (EXEL)

Healthcare
$64.63
▼ −1.82%
LAST CLOSE · NOV 20

Exelixis develops and sells cancer medicines, led by CABOMETYX, for physicians and their patients. It last closed at $64.63 on Nov 20, down 1.82% on the day. The next earnings report for EXEL is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Oct 2026, EXEL reported EPS of $0.85 on revenue of $658.7M, with revenue up 10.2% from a year ago. Over its last 8 reports the stock moved an average of 8.4% the session after earnings. Over the last 12 months EXEL insiders bought $1.2M of stock on the open market and sold $34.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is EXEL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold EXEL.

Key Stats

Last 12 months
Results
Revenue
$2.5B
+9.1% vs a year ago
Net income
$885.1M
+30.6% vs a year ago
EPS (diluted)
$3.34
+40.3% vs a year ago
Free cash flow
$1.2B
46.5% margin
Valuation
Market cap
$15.8B
244.0M shares
P/E
19.4
Price over 12 month EPS
Price to sales
6.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$304.8M
At Oct 2
Shareholder equity
$1.8B
Buybacks
$1.3B
Last 12 months
Fiscal year endsJanuary
ExchangeNasdaq
Financials history
FY2021: $1.4B$1.4BFY2021FY2022: $1.6B$1.6BFY2022FY2023: $1.8B$1.8BFY2023FY2025: $2.2B$2.2BFY2025FY2026: $2.3B$2.3BFY2026

From EXEL's SEC filings, latest 10-Q for the period ending Oct 2, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · After the close
Reported EPS
$0.85
Quarter ended Oct 2026
Year ago EPS
$0.69
+23.2% on a GAAP basis
Revenue
$658.7M
+10.2% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Jan 2025: $0.48Jan '25Apr 2025: $0.55Apr '25Jul 2025: $0.65Jul '25Oct 2025: $0.69Oct '25Jan 2026: $0.88Jan '26Apr 2026: $0.79Apr '26Jul 2026: $0.82Jul '26Oct 2026: $0.85Oct '26Latest $0.85
Revenue by quarter
Jan 2025: $566.8MJan '25Apr 2025: $555.4MApr '25Jul 2025: $568.3MJul '25Oct 2025: $597.8MOct '25Jan 2026: $598.7MJan '26Apr 2026: $610.8MApr '26Jul 2026: $628.7MJul '26Oct 2026: $658.7MOct '26Latest $658.7M
How EXEL moved after its last 8 reports
Average move the session after a report ±8.4%
Oct 29, 2026After the close+4.8%
Aug 5, 2026After the close−7.9%
May 5, 2026After the close+9.6%
Jan 12, 2026After the close+0.1%
Nov 4, 2025After the close+6.5%
Jul 28, 2025After the close−16.8%
May 13, 2025After the close+20.8%
Jan 13, 2025After the close+1.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on EXELStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on EXEL
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on EXEL

Technical Analysis

EXEL · as of the Nov 20 close · updated each morning
Moving sideways

The stock sits between its 20 and 50 day averages. It is 18% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 43). The nearest support is the Pivot S1 at $63.74, and the nearest resistance the Pivot at $65.34.

Short trendNeutral
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 3.5%/day
Key levels
$73.6952 week high+14.0%
$73.69Swing high (Nov 5)+14.0%
$68.6020 day average+6.1%
$66.23Pivot R1+2.5%
$65.34Pivot+1.1%
$64.63Last close
$63.74Pivot S1−1.4%
$63.2050 day average−2.2%
$59.24100 day average−8.3%
$57.02Swing low (Oct 6)−11.8%
$52.86200 day average−18.2%
$39.7152 week low−38.6%
Indicators
RSI (14)43.41Middle of its rangeNeutral
MACD0.99Below its signal lineBearish
Stochastic11.7Near the bottom of its rangeOversold
ADX (14)31.3Trending down
Williams %R-98.0Oversold below −80, overbought above −20Oversold
CCI (20)-112.4Oversold below −100, overbought above 100Oversold
Rate of change−7.1%Change over 10 sessionsBearish
ATR (14)$2.25Typical daily range, 3.5% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for EXEL

What happened before

See how EXEL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow EXEL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How EXEL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for EXELHow many large options trades hit EXEL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

EXEL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●364 buying vs 347 selling
  • ▼Held by funds -4.2 pts
  • ▲Funds holding +17
  • ▼Superinvestors: 0 added, 4 cut
  • ▼Put/call 0.89 to 1.57
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding778761+2.2%
In funds' top 10129+33.3%
Held by funds102.3%106.5%−4.2 pts
New / increased96 / 268123 / 257−4.2%
Reduced / sold out273 / 74281 / 69−0.9%
Put/call ratio1.570.89+77.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EXEL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

EXEL Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$1.2M1 buy · 1 insider
Sold$34.8M20 sales · 11 insiders
20% of the selling was under pre-arranged trading plans.
2026-02 sold $20.6M2026-05 sold $9.9M2026-06 sold $690K2026-08 sold $527KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 10Mary C BeckerleDirectorSale plan9,812$53.66$527K
Jun 1Sue Gail EckhardtDirectorSale plan9,812$50.14$492K
Jun 1Jack L WyszomierskiDirectorSale plan3,925$50.55$198K
May 26Dana AftabEVP, Research and DevelopmentSale43,451$50.35$2.2M
May 20Patrick J. HaleyEVP, CommercialSale32,110$49.81$1.6M
May 18Brenda HeftiSVP and General CounselSale plan6,625$50.21$333K
Every insider buy and sale for EXEL over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See EXEL insider trades →

From SEC Form 4 filings by EXEL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EXEL is in one of them and how their past EXEL trades turned out.

EXEL in the AI portfolios
Loading…

EXEL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EXEL in an article yet. Here's the latest on the wider market.

EXEL in the news

EXEL Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Apr 27
Who traded EXEL · since 2019
Latest 4 filings
$1K – $15KTraded Jun 4, 2019Filed Apr 27, 2020
Donna ShalalaSell (partial)
$1K – $15KTraded Apr 16, 2019Filed Apr 27, 2020
$1K – $15KTraded Feb 6, 2019Filed Apr 27, 2020
$1K – $15KTraded Jan 9, 2019Filed Apr 27, 2020
PersonTypeAmountTradedFiledDelay
Donna ShalalaD · FLSell$1K – $15KJun 4, 2019Apr 27, 2020328 d
Donna ShalalaD · FLSell (partial)$1K – $15KApr 16, 2019Apr 27, 2020377 d
Donna ShalalaD · FLBuy$1K – $15KFeb 6, 2019Apr 27, 2020446 d
Donna ShalalaD · FLBuy$1K – $15KJan 9, 2019Apr 27, 2020474 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Exelixis

Exelixis is a biopharmaceutical company based in Alameda, California, that develops and sells medicines for cancer. Its main product is CABOMETYX, a cabozantinib tablet used to treat several forms of kidney, liver, thyroid and neuroendocrine cancer, and it also sells COMETRIQ for medullary thyroid cancer. Its medicines are prescribed by physicians and taken by patients, with partners such as Ipsen and Takeda handling sales in markets outside the U.S. Its pipeline includes zanzalintinib, which is under review for colorectal cancer.

Headquarters
Alameda, CA
Founded
1994